

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
NHL-NP-43SERIAL NO.
10/646,620INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

APPLICANT

WITTIG et al.

FILING DATE

August 22, 2003

GROUP

1645

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
AA						
AB						
AC						
AD						
AE						
AF						
AG						
AH						
AI						
AJ						
AK						

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
AL	9 9 1 0 2 8 1	12/1999	International			X	
AM	9 9 2 2 1 0 3	9/1999	International			X	
AN	19 8 2 6 7 5 8	10/1999	Fed. Rep. of Germany				X
AO	0 9 6 7 2 7 4	12/1999	Europe				X
AP	0 9 4 1 3 1 8		Europe			X	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AQ	J Managed Care Pharm 1999: 414-419.
AR	Stein et al., Proc. Nat. Acad. Sci. USA 87, 5935-5939 (1990).
AS	Stein et al., J. Neuroscience 10, 1292-1298 (1990).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INITIALS vwtDATE MAILED 2/18/2004

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
(Rev. 2-32) PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.
NHL-NP-43

SERIAL NO.
10/646,620

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

APPLICANT

WITTIG et al.

FILING DATE

August 22, 2003

GROUP

1645

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
AA						
AB						
AC						
AD						
AE						
AF						
AG						
AH						
AI						
AJ						
AK						

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
AL							
AM							
AN							
AO							
AP							

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AQ ⁱ	Cabot et al. J. Clin. Invest. 100, 142-148 (1997).
AR ⁱ	Schäfer et al. Proc. Nat. Acad. Sci. USA 91, 4219-4233.
AS ⁱ	ibid. 93, 6096-6100 (1996).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered; whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INITIALS vwt

DATE MAILED 2/18/2004

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
(Rev. 2-32) PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.
NHL-NP-43

SERIAL NO.
10/646,620

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

APPLICANT

WITTIG et al.

(Use several sheets if necessary)

FILING DATE
August 22, 2003

GROUP
1645

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA					
	AB					
	AC					
	AD					
	AE					
	AF					
	AG					
	AH					
	AI					
	AJ					
	AK					

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	AL						
	AM						
	AN						
	AO						
	AP						

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	AQ ²	Machelska et al., Nature Medicine 4, 1425-1428 (1998),
	AR ²	Machelska and Stein, Current Opinion in Anaesthesiology 1999, 579-581,
	AS ¹	Ishii et al. (Experimental Neurology 166, 90-98 (2000),

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INITIALS vw

DATE MAILED 2/18/2004

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
(Rev. 2-32) PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.
NHL-NP-43

SERIAL NO.
10/646,620

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

APPLICANT

WITTIG et al.

FILING DATE

August 22, 2003

GROUP

1645

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
AA						
AB						
AC						
AD						
AE						
AF						
AG						
AH						
AI						
AJ						
AK						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
		YES	NO											
	AL													
	AM													
	AN													
	AO													
	AP													

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AQ ³	Lu et al. (Neural Transplant Plast 4, 15-26 (1993).
AR ³	Feingold and Iadarola (Hum Gene Therapy 10 (7): 1251-7 (1999).
AS ³	Wilson et al. (Proc Natl Acad Sci USA 96, 3211-6 (1999).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INITIALS

vwt

DATE MAILED 2/18/2004

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
(Rev. 2-32) PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.
NHL-NP-43

SERIAL NO.
10/646,620

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

APPLICANT
WITTIG et al.

(Use several sheets if necessary)

FILING DATE
August 22, 2003

GROUP
1645

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
AA						
AB						
AC						
AD						
AE						
AF						
AG						
AH						
AI						
AJ						
AK						

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
AL							
AM							
AN							
AO							
AP							

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AQ ^f	Grauerholz et al., Peptides 19, 939-948 (1998).
AR ^f	Bauer M. et al., Abstract Sun27, 31th Conference 2000 INRC, July 16 th to July 18 th 2000, Seattle, Washington USA.
AS ^f	Chemin I. et al., J. Viral Hepat. Nov; 5(6) 369-75, 1998.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INITIALS vwt

DATE MAILED 2/18/2004

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
(Rev. 2-32) PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.
NHL-NP-43

SERIAL NO.
10/646,620

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

APPLICANT

WITTIG et al.

(Use several sheets if necessary)

FILING DATE
August 22, 2003

GROUP
1645

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA					
	AB					
	AC					
	AD					
	AE					
	AF					
	AG					
	AH					
	AI					
	AJ					
	AK					

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
						YES NO
	AL					
	AM					
	AN					
	AO					
	AP					

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AQ	Tanelian et al., "Gene Therapy with Adenoviral B-Endorphin is Antinociceptive," Anesthesiology, American Society of Anesthesiologists, Philadelphia, PA., USA, Bd. 85, Nr. 3A, September 1996 (09/1996);
AR	Schafer et al., "Interleukin 1 beta and corticotropin-releasing factor inhibit pain by releasing opioids from immune cells in inflamed tissue," Proceedings of the National Academy of Sciences of the United States of America, U.S., May 10, 1994, Bd. 91, Nr. 10, May 10, 1994 (05/10/1994), Pages 4219-4223, XP002211429, ISSN: 0027-8424;
AS	Database EMBL 'Online', EMBL; January 28, 1986 (01/28/1986), "EMBL:RNCRRF - Rat mRNA for corticotropin-releasing factor precursor (prepro-CRF)" retrieved from WWW.EBI.AC.UK, Database accession no. X03036, XP002211430;

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INITIALS ywt

DATE MAILED 2/18/2004

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
(Rev. 2-32) PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

NHL-NP-43

SERIAL NO.

10/646,620

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

APPLICANT

WITTIG et al.

FILING DATE

August 22, 2003

GROUP

1645

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
AA						
AB						
AC						
AD						
AE						
AF						
AG						
AH						
AI						
AJ						
AK						

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
AL							
AM							
AN							
AO							
AP							

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AQ ^b	Database EMBL 'Online', EMBL; July 29, 1991 (07/29/1991), "EMBL:HSP0MC9 - Human proopiomelanocortin (POMC) gene, exon 3." retrieved from WWW.EBI.AC.UK; Database accession no. J00292, XP002211431;
AR ^c	Chang et al.; "Structural organization of human genomic DNA encoding the pro-opiomelanocortin peptide," Proceedings of the National Academy of Sciences of the United States of America, United States Aug. 1980, Bd. 77, Nr. 8, August 1980 (08/1980), pages 4890-4894, XP001095590, ISSN: 0027-8424;
AS ^b	Database EMBL 'Online', EMBL; June 13, 1985 (06/13/1985), "EMBL:RNP0MC3 - Rat proopiomelanocortin (POMC) gene, exon 3." retrieved from WWW.EBI.AC.UK, Database accession no. J00759, XP002211432; and

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INITIALS vwt

DATE MAILED 2/18/2004

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
(Rev. 2-32) PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.
NHL-NP-43

SERIAL NO.
10/646,620

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

APPLICANT

WITTIG et al.

FILING DATE

August 22, 2003

GROUP

1645

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
AA						
AB						
AC						
AD						
AE						
AF						
AG						
AH						
AI						
AJ						
AK						

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
AL							
AM							
AN							
AO							
AP							

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AQ ⁷	Wilson et al., "Herpes virus-mediated preproenkephalin gene transfer to the amygdala is antinociceptive," Brain Research, 792, 133-5 (1998)
AR ⁷	
AS ⁷	

EXAMINER.

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INITIALS vwt

DATE MAILED 2/18/2004